

09/522,342

Patent Docket P1219P1

Group II: Claims 23-33 and 40, drawn to a polypeptide, classified in class 530, subclass 350, for example;

Group III: Claims 34-37 and 40, drawn to an antibody to a polypeptide, classified in class 530, subclass 387.1, for example;

Group IV: Claims 38 and 40, drawn to a compound of unspecified constitution (identified as an agonist), class undeterminable, subclass undeterminable;

Group V: Claims 39-40, drawn to a compound of unspecified constitution (identified as an antagonist), class undeterminable, subclass undeterminable;

Group VI: Claim 41, drawn to a method of screening for a binding agent (using the polypeptide), class 436, subclass 501, for example;

Group VII: Claims 42-44, drawn to a method of screening for modulation of activity (using the polypeptide), classified in class 435, subclass 4, for example;

Group VIII: Claims 45-48, drawn to a method of identifying a receptor (using the polypeptide), classified in class 436, subclass 501, for example.

Group IX: Claims 49-50, drawn to a method of inducing leptin release (using the polypeptide), classified in class 514, subclass 2, for example;

Group X: Claims 49 and 51, drawn to a method of inducing leptin release (using the polynucleotide), classified in class 514, subclass 44, for example;

Group XI: Claims 52-53, drawn to a method of inducing a decrease in glucose uptake (using the polypeptide), classified in class 514, subclass 2, for example.

Group XII: Claims 52 and 54, drawn to a method of inducing a decrease in glucose uptake (using the polynucleotide), classified in class 514, subclass 44, for example;

Group XIII: Claims 55-57 and 59-60, drawn to a method of treating obesity (using the polypeptide), classified in class 514, subclass 2, for example;

Group XIV: Claims 55-56 and 58-59, drawn to a method of treating obesity (using the polynucleotide), classified in class 514, subclass 44, for example;

09/522,342

Patent Docket P1219P1

Group XV: Claims 61-62 and 64-66, drawn to a method of reducing body mass (using the polypeptide), classified in class 514, subclass 2, for example;

Group XVI: Claims 61 and 63-65, drawn to a method of reducing body mass (using the polynucleotide), classified in class 514, subclass 44, for example;

Group XVII: Claims 67-68 and 70-71, drawn to a method of reducing triglycerides (using the polypeptide), classified in class 514, subclass 2, for example;

Group XVIII: Claims 67 and 69-70, drawn to a method of reducing triglycerides (using the polynucleotide), classified in class 514, subclass 44, for example;

Group XIX: Claims 72-73 and 75-76, drawn to a method of increasing metabolic rate (using the polypeptide), classified in class 514, subclass 2, for example;

Group XX: Claims 72 and 74-75, drawn to a method of increasing metabolic rate (using the polynucleotide), classified in class 514, subclass 44, for example; and

Group XXI: Claim 77, drawn to a transgenic animal, classified in class 800, subclass 2.

Applicants hereby elect to prosecute the invention of Group I, Claims 1-22, drawn to polynucleotides, vectors, host cells and methods of making a polypeptide.

#### **REMARKS**

Applicants reserve their rights to file divisional applications for the non-elected claims, as well as any other matter disclosed in the present application which is not encompassed by the elected claims.

#### **Conclusion:**

Applicants respectfully request that the above-made election and remarks be made of record in the file history of the instant application.